Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques

Marta Marthas, Koen K.A. Van Rompay, Zachary Abbott, Patricia Earl, Linda Buonocore-Buzzelli, Bernard Moss, Nina F. Rose, John K. Rose, Pamela A. Kozlowski, Kristina Abel

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Despite antiretroviral medications, the rate of pediatric HIV-1 infections through breast-milk transmission has been staggering in developing countries. Therefore, the development of a vaccine to protect vulnerable infant populations should be actively pursued. We previously demonstrated that oral immunization of newborn macaques with vesicular stomatitis virus expressing simian immunodeficiency virus genes (VSV-SIV) followed 2 weeks later by an intramuscular boost with modified vaccinia ankara virus expressing SIV (MVA-SIV) successfully induced SIV-specific T and B cell responses in multiple lymphoid tissues, including the tonsil and intestine [13]. In the current study, we tested the oral VSV-SIV prime/systemic MVA-SIV boost vaccine for efficacy against multiple oral SIVmac251 challenges starting two weeks after the booster vaccination. The vaccine did not prevent SIV infection. However, in vaccinated infants, the level of SIV-specific plasma IgA (but not IgG) at the time of challenge was inversely correlated with peak viremia. In addition, the levels of SIV-specific IgA in saliva and plasma were inversely correlated with viral load at euthanasia. Animals with tonsils that contained higher frequencies of SIV-specific TNF-α- or IFN-γ-producing CD8+ T cells and central memory T cells at euthanasia also had lower viremia. Interestingly, a marked depletion of CD25+FoxP3+CD4+ T cells was observed in the tonsils as well as the intestine of these animals, implying that T regulatory cells may be a major target of SIV infection in infant macaques. Overall, the data suggest that, in infant macaques orally infected with SIV, the co-induction of local antiviral cytotoxic T cells and T regulatory cells that promote the development of IgA responses may result in better control of viral replication. Thus, future vaccination efforts should be directed towards induction of IgA and mucosal T cell responses to prevent or reduce virus replication in infants.

Original languageEnglish (US)
Pages (from-to)3124-3137
Number of pages14
JournalVaccine
Volume29
Issue number17
DOIs
StatePublished - Apr 12 2011

Fingerprint

SAIDS Vaccines
Vesiculovirus
Simian immunodeficiency virus
Simian Immunodeficiency Virus
Vaccinia virus
Vesicular Stomatitis
Macaca
mouth
T-lymphocytes
vaccines
Viruses
T-Lymphocytes
Immunoglobulin A
tonsils
Palatine Tonsil
Genes
Euthanasia
genes
Viremia
viremia

Keywords

  • Mucosal immunity
  • Pediatric HIV vaccine
  • SIV

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Marthas, M., Van Rompay, K. K. A., Abbott, Z., Earl, P., Buonocore-Buzzelli, L., Moss, B., ... Abel, K. (2011). Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques. Vaccine, 29(17), 3124-3137. https://doi.org/10.1016/j.vaccine.2011.02.051

Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques. / Marthas, Marta; Van Rompay, Koen K.A.; Abbott, Zachary; Earl, Patricia; Buonocore-Buzzelli, Linda; Moss, Bernard; Rose, Nina F.; Rose, John K.; Kozlowski, Pamela A.; Abel, Kristina.

In: Vaccine, Vol. 29, No. 17, 12.04.2011, p. 3124-3137.

Research output: Contribution to journalArticle

Marthas, M, Van Rompay, KKA, Abbott, Z, Earl, P, Buonocore-Buzzelli, L, Moss, B, Rose, NF, Rose, JK, Kozlowski, PA & Abel, K 2011, 'Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques', Vaccine, vol. 29, no. 17, pp. 3124-3137. https://doi.org/10.1016/j.vaccine.2011.02.051
Marthas, Marta ; Van Rompay, Koen K.A. ; Abbott, Zachary ; Earl, Patricia ; Buonocore-Buzzelli, Linda ; Moss, Bernard ; Rose, Nina F. ; Rose, John K. ; Kozlowski, Pamela A. ; Abel, Kristina. / Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques. In: Vaccine. 2011 ; Vol. 29, No. 17. pp. 3124-3137.
@article{e4c6392fd94f433b8b6d027aa46ab540,
title = "Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques",
abstract = "Despite antiretroviral medications, the rate of pediatric HIV-1 infections through breast-milk transmission has been staggering in developing countries. Therefore, the development of a vaccine to protect vulnerable infant populations should be actively pursued. We previously demonstrated that oral immunization of newborn macaques with vesicular stomatitis virus expressing simian immunodeficiency virus genes (VSV-SIV) followed 2 weeks later by an intramuscular boost with modified vaccinia ankara virus expressing SIV (MVA-SIV) successfully induced SIV-specific T and B cell responses in multiple lymphoid tissues, including the tonsil and intestine [13]. In the current study, we tested the oral VSV-SIV prime/systemic MVA-SIV boost vaccine for efficacy against multiple oral SIVmac251 challenges starting two weeks after the booster vaccination. The vaccine did not prevent SIV infection. However, in vaccinated infants, the level of SIV-specific plasma IgA (but not IgG) at the time of challenge was inversely correlated with peak viremia. In addition, the levels of SIV-specific IgA in saliva and plasma were inversely correlated with viral load at euthanasia. Animals with tonsils that contained higher frequencies of SIV-specific TNF-α- or IFN-γ-producing CD8+ T cells and central memory T cells at euthanasia also had lower viremia. Interestingly, a marked depletion of CD25+FoxP3+CD4+ T cells was observed in the tonsils as well as the intestine of these animals, implying that T regulatory cells may be a major target of SIV infection in infant macaques. Overall, the data suggest that, in infant macaques orally infected with SIV, the co-induction of local antiviral cytotoxic T cells and T regulatory cells that promote the development of IgA responses may result in better control of viral replication. Thus, future vaccination efforts should be directed towards induction of IgA and mucosal T cell responses to prevent or reduce virus replication in infants.",
keywords = "Mucosal immunity, Pediatric HIV vaccine, SIV",
author = "Marta Marthas and {Van Rompay}, {Koen K.A.} and Zachary Abbott and Patricia Earl and Linda Buonocore-Buzzelli and Bernard Moss and Rose, {Nina F.} and Rose, {John K.} and Kozlowski, {Pamela A.} and Kristina Abel",
year = "2011",
month = "4",
day = "12",
doi = "10.1016/j.vaccine.2011.02.051",
language = "English (US)",
volume = "29",
pages = "3124--3137",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "17",

}

TY - JOUR

T1 - Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques

AU - Marthas, Marta

AU - Van Rompay, Koen K.A.

AU - Abbott, Zachary

AU - Earl, Patricia

AU - Buonocore-Buzzelli, Linda

AU - Moss, Bernard

AU - Rose, Nina F.

AU - Rose, John K.

AU - Kozlowski, Pamela A.

AU - Abel, Kristina

PY - 2011/4/12

Y1 - 2011/4/12

N2 - Despite antiretroviral medications, the rate of pediatric HIV-1 infections through breast-milk transmission has been staggering in developing countries. Therefore, the development of a vaccine to protect vulnerable infant populations should be actively pursued. We previously demonstrated that oral immunization of newborn macaques with vesicular stomatitis virus expressing simian immunodeficiency virus genes (VSV-SIV) followed 2 weeks later by an intramuscular boost with modified vaccinia ankara virus expressing SIV (MVA-SIV) successfully induced SIV-specific T and B cell responses in multiple lymphoid tissues, including the tonsil and intestine [13]. In the current study, we tested the oral VSV-SIV prime/systemic MVA-SIV boost vaccine for efficacy against multiple oral SIVmac251 challenges starting two weeks after the booster vaccination. The vaccine did not prevent SIV infection. However, in vaccinated infants, the level of SIV-specific plasma IgA (but not IgG) at the time of challenge was inversely correlated with peak viremia. In addition, the levels of SIV-specific IgA in saliva and plasma were inversely correlated with viral load at euthanasia. Animals with tonsils that contained higher frequencies of SIV-specific TNF-α- or IFN-γ-producing CD8+ T cells and central memory T cells at euthanasia also had lower viremia. Interestingly, a marked depletion of CD25+FoxP3+CD4+ T cells was observed in the tonsils as well as the intestine of these animals, implying that T regulatory cells may be a major target of SIV infection in infant macaques. Overall, the data suggest that, in infant macaques orally infected with SIV, the co-induction of local antiviral cytotoxic T cells and T regulatory cells that promote the development of IgA responses may result in better control of viral replication. Thus, future vaccination efforts should be directed towards induction of IgA and mucosal T cell responses to prevent or reduce virus replication in infants.

AB - Despite antiretroviral medications, the rate of pediatric HIV-1 infections through breast-milk transmission has been staggering in developing countries. Therefore, the development of a vaccine to protect vulnerable infant populations should be actively pursued. We previously demonstrated that oral immunization of newborn macaques with vesicular stomatitis virus expressing simian immunodeficiency virus genes (VSV-SIV) followed 2 weeks later by an intramuscular boost with modified vaccinia ankara virus expressing SIV (MVA-SIV) successfully induced SIV-specific T and B cell responses in multiple lymphoid tissues, including the tonsil and intestine [13]. In the current study, we tested the oral VSV-SIV prime/systemic MVA-SIV boost vaccine for efficacy against multiple oral SIVmac251 challenges starting two weeks after the booster vaccination. The vaccine did not prevent SIV infection. However, in vaccinated infants, the level of SIV-specific plasma IgA (but not IgG) at the time of challenge was inversely correlated with peak viremia. In addition, the levels of SIV-specific IgA in saliva and plasma were inversely correlated with viral load at euthanasia. Animals with tonsils that contained higher frequencies of SIV-specific TNF-α- or IFN-γ-producing CD8+ T cells and central memory T cells at euthanasia also had lower viremia. Interestingly, a marked depletion of CD25+FoxP3+CD4+ T cells was observed in the tonsils as well as the intestine of these animals, implying that T regulatory cells may be a major target of SIV infection in infant macaques. Overall, the data suggest that, in infant macaques orally infected with SIV, the co-induction of local antiviral cytotoxic T cells and T regulatory cells that promote the development of IgA responses may result in better control of viral replication. Thus, future vaccination efforts should be directed towards induction of IgA and mucosal T cell responses to prevent or reduce virus replication in infants.

KW - Mucosal immunity

KW - Pediatric HIV vaccine

KW - SIV

UR - http://www.scopus.com/inward/record.url?scp=79954591698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954591698&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.02.051

DO - 10.1016/j.vaccine.2011.02.051

M3 - Article

C2 - 21377510

AN - SCOPUS:79954591698

VL - 29

SP - 3124

EP - 3137

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 17

ER -